European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates An Opinion From CHMP No Later Than July 2024
European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates An Opinion From CHMP No Later Than July 2024
歐洲藥品管理局已將對Apellis Pharmicals的玻璃體內Pegcetacoplan地理萎縮的審查重置爲初步評估的最後階段（第180天）。Apellis 預計 CHMP 不遲於 2024 年 7 月發表意見
European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates An Opinion From CHMP No Later Than July 2024
歐洲藥品管理局已將對Apellis Pharmicals的玻璃體內Pegcetacoplan地理萎縮的審查重置爲初步評估的最後階段（第180天）。Apellis 預計 CHMP 不遲於 2024 年 7 月發表意見
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。